相关实验视频

Updated: Jul 25, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

基于PD-1/PD-L1抑制剂的单疗法和脑转移性NSCLC的组合治疗之间的结果差异

Haowei Wang¹, Fangfang Liu², Xiaoxia Chen¹

¹Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Zhengmin Road 507, Shanghai, 200433, China.

Experimental hematology & oncology

|June 23, 2023

概括

对于患有脑转移的非小细胞肺癌患者,PD-1/PD-L1抑制剂单一治疗由于免疫抑制瘤微环境而提供有限的益处. 组合疗法,特别是与抗血管原体的药物,显著改善结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症转移癌症转移

背景情况:

使用PD-1/PD-L1抑制剂治疗脑转移的非小细胞肺癌 (NSCLC) 的最佳治疗方法尚不清楚.
对于指导治疗策略而言,BrM的免疫类型定型至关重要.

研究的目的:

评估基于PD-1/PD-L1抑制剂的疗法在患有BrMs的NSCLC患者中的疗效.
为了研究BrMs的瘤免疫微环境 (TIME).

主要方法:

对308名用PD-1/PD-L1抑制剂 (单疗或联合疗法) 治疗的NSCLC患者的回顾性分析.
卡普兰-梅尔曲线和对结果评估的日志等级测试.
对原发性瘤和BrM进行转录组分析,以表征TIME.

主要成果:

在患有BrMs的患者中,PD-1/PD-L1抑制剂单疗显示出较低的无进展存活率 (PFS) 和整体存活率 (OS).
组合疗法,特别是与抗血管原体药物,显著改善了PFS和OS在患者的brms.
BrMs表现出抑制的时间,CD4+ T细胞和M1巨细胞减少,M2巨细胞增加.

结论:

由于免疫抑制的时间,PD-1/PD-L1抑制剂单疗对具有BrMs的NSCLC提供了有限的益处.
组合治疗,特别是PD-1/PD-L1抑制剂加上抗血管性疗法,可以提高患有BrMs的NSCLC患者的临床结果.

关键词:

大脑转移是大脑的转移.肺癌是一种肺癌.在PD-1中使用PD-1.瘤的免疫微环境

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...